Recent Blog Articles

Statins and cancer

November 01, 2007

The first statin drug was approved for clinical use in the United States in 1987. Doctors quickly recognized that lovastatin (Mevacor) had an excellent effect on blood cholesterol levels, but they worried about possible side effects. In the next 20 years, the statin family grew to its current roster of six drugs. A seventh, cerivastatin (Baycol), was withdrawn because of muscle toxicity, but the others have proved safe — and they've shown an unrivaled ability to reduce LDL ("bad") cholesterol levels and cut the risk of heart attacks and cardiovascular deaths.

Since statins are the largest-selling prescription drugs in this country, doctors have wondered if they may have benefits beyond the heart. Indeed, statins produce a substantial reduction in the risk of stroke. And although the results are less conclusive, statins are being studied for possible benefits against a variety of diseases, from cataracts and dementia to chronic lung disease, osteoporosis, and the flu. And now attention is turning to statins and cancer.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».

Disclaimer:

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.